Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term oral KP-001 study in vascular malformations
jRCT2041230065Phase 3Active, not recruiting
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of KP001 in vascular malformation, venous malformation (VM), lymphangioma and 11 more (3 cohorts), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Adverse events, Vital signs and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
KP001
03
Conditions
vascular malformationvenous malformation (VM)lymphangiomaKlippel-Trenaunay syndrome (KTS)Megalencephaly-Capillary Malformation Syndrome (MCAP)
Beyond the preview
Go deeper on jRCT2041230065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230065.